Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Rodatristat Ethyl in Healthy Volunteers
NCT05933447Phase 1Completed
- Sponsor
- Altavant Sciences
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rodatristat in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Altavant Sciences. Primary endpoint: Fridericia-corrected QT interval at 20 Days. Started May 2023; status: completed.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05933447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933447.